scholarly journals GESTATIONAL DIABETES MELLITUS;

2019 ◽  
Vol 26 (01) ◽  
Author(s):  
Khiaynat Sarwar Hashmi ◽  
Tasneem Akhtar ◽  
Sidrah Batool ◽  
Kokab Saleem
Keyword(s):  
Diabetes Mellitus ◽  
Weight Gain ◽  
Gestational Diabetes ◽  
Gestational Diabetes Mellitus ◽  
Blood Sugar ◽  
Neonatal Outcome ◽  
Regular Insulin ◽  
Insulin Group ◽  
Metformin Group ◽  
Number Of Patients

Objectives: To Compare metformin and regular insulin in blood sugar control and neonatal outcome in patients with gestational diabetes mellitus. Material and Method:… Study Design:  Randomized control trial. Place of the Study: Department of Gynecology and Obstetrics, Bahawal Victoria hospital Bahawalpur. Duration of the study.1 year 1st January 2017- 31st December 2017. Sample Size: N=200, one half (group A) receiving Metformin and other half (group B) receiving regular insulin. Results: Blood sugar control depicted by fasting, 2 hr post parandial levels and HbA1c % was similar in both group.coexisting hypertensive complications were seen more in insulin group. Weight gain was also significantly more in insulin group 17 kg on an average as compared to metformin group where average weight gain was 13 kg.Convenience and satisfaction regarding their treatment,more number of patients were satisfied in metformin group. There were significant increase in the mean birth weight of the newborns, need for admission in NICU and Neonatal hypoglycemia in insulin group as compared to metformin group. Conclusion: Metformin when compared to insulin has equal efficacy in controlling maternal blood sugar levels but better neonatal outcome, patient satisfaction and convenience in treatment of gestational Diabetes Mellitus.

scholarly journals The Effect of Oat Bran Supplement on Fasting Blood Sugar and Glycosylated Hemoglobin in Patients with Gestational Diabetes Mellitus: Single-blind Randomized Clinical Trial

2019 ◽  
Author(s):  
Maedeh Shahzeidi ◽  
Azadeh Nadjarzadeh ◽  
Masoud Rahmanian ◽  
Amin Salehi Abarghuoei ◽  
Hossein Fallahzadeh ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Clinical Trial ◽  
Weight Gain ◽  
Gestational Diabetes ◽  
Gestational Diabetes Mellitus ◽  
Blood Sugar ◽  
Glycosylated Hemoglobin ◽  
Oat Bran ◽  
Single Blind ◽  
Hba1c Levels

Background: Gestational diabetes mellitus (GDM) is known as a degree of glucose intolerance that occurs for the first time during pregnancy. There is paucity of evidence regarding the effect of oat bran on GDM. Oat as a source of β-glucan can be effective in reducing the blood sugar levels. This study aimed to investigate the effect of oat bran on fasting blood sugar (FBS) and glycosylated hemoglobin (HbA1c) in patients with GDM. Method: This single-blind clinical trial was conducted on 90 pregnant women with GDM. The experimental group (EG) consumed 30 g of oat bran daily with 100 g of low-fat yogurt before lunch and dinner for 4 weeks. The control group (CG) consumed only low-fat yogurt and both groups received nutrition counseling. The present study investigated the FBS, HbA1c, and weight gain at the beginning and after four weeks of intervention. Results: Out of 90 patients, 80 completed the study. FBS decreased in the EG (P = 0.04, -2.75 ± 8.22), whereas, it increased in the CG (P = 0.003, 4.37 ± 8.72). No significant difference was observed between the two groups in terms of HbA1c levels. Weight gain was controlled more efficiently in the EG than the CG (P = 0.001). Conclusion: The use of oat bran for four weeks decreased the FBS,; whereas, it did not affect HbA1c levels. Weight gain was controlled better in the EG than the CG.

scholarly journals Investigation the Effects of Metformin versus Insulin on Neonatal and Maternal Outcomes in Women with Gestational Diabetes Mellitus: A Randomized Clinical Trail

2016 ◽  
Vol 9 (4) ◽  
pp. 272 ◽  
Author(s):  
Mahin Najafian ◽  
Mojgan Barati ◽  
Sara Masihi ◽  
Ailin Fardipor
Keyword(s):  
Diabetes Mellitus ◽  
Gestational Diabetes ◽  
Gestational Diabetes Mellitus ◽  
Neonatal Outcomes ◽  
Neonatal Hypoglycemia ◽  
Singleton Pregnancy ◽  
Insulin Group ◽  
Metformin Group ◽  
Maternal And Neonatal Outcomes ◽  
The Mean

The aim of this study was to evaluate the effectiveness of metformin versus insulin in the glycemic control and to investigate the maternal and neonatal outcomes in in women with gestational diabetes mellitus. Pregnant women with gestational diabetes were randomized to either receive metformin (n=70) or insulin (n=70). Inclusion criteria were singleton pregnancy, following healthy diet and performing exercise for at least one week without satisfactory blood glucose level, no risk factor contributing to lactic acidosis, and no anatomic and/or chromosome anomalies. Two patients were excluded from the study due to lost to follow-up. The mean score of BMI and FBS after treatment was similar between two groups. But, the mean score of 2 hours blood sugar in insulin group (104.38±7.06 mg/dl) was significantly higher than metformin group (97.5±5.98 mg/dl) (P<0.0001). The weight gain in metformin group was slightly lower than insulin group. (P=0.123). The proportion of neonatal hypoglycemia in insulin group was higher than metformin group (20 vs 3, P=0.002). Other neonatal outcomes such as IUGR, IUFD, fetal anomaly, polyhydramnios, macrosomia, oligohydramnios, and NICU stay did not differ significantly between two groups. In conclusion, metformin had compatible effect with insulin in decreasing adverse maternal and neonatal outcomes even in some parameters such as neonatal hypoglycemia it works better. Totally, metformin is safe and effectiveness in controlling the gestational diabetes mellitus.

Efficacy and Safety of Metformin in Gestational Diabetes Mellitus

2020 ◽  
Keyword(s):  
Diabetes Mellitus ◽  
Weight Gain ◽  
Gestational Diabetes ◽  
Gestational Diabetes Mellitus ◽  
Gestational Age ◽  
Metabolic Effects ◽  
Control Group ◽  
Minimal Risk ◽  
Insulin Group ◽  
Diet Control

Background: Gestational Diabetes Mellitus (GDM) is a sequence of serious unfavorable maternal and perinatal outcomes specially if uncontrolled. Although insulin is a standard therapy, Metformin can be used as an alternative medication to insulin. This study aimed to establish the efficacy, safety, and other metabolic effects of metformin in GDM due to limited studies in the local population. Methods: This quasi experimental trial was conducted on pregnant female at 24 weeks of gestation and above, presenting to Ziauddin Hospital. A total of 361 patients who were diagnosed with GDM were enrolled. Patients were divided into three groups: diet control, metformin, and metformin with insulin. The Chi Square and ANOVA were used to compare the maternal and neonatal outcomes. Further post hoc analysis of significant parameters was done using Tukey HSD test. Results: Weight gain in pregnancy and gestational age at delivery gives significant mean differences across three study groups (p=<0.01). In diet control group, weight was significantly gained as compare to metformin group. Similarly, the gestational age in diet control group was significantly higher as compare to metformin and metformin with insulin group (p=<0.01). The higher gestational age was found in patients treated with metformin as compared to metformin with insulin group (37.25±1.41). Conclusion: Metformin alone as well as in combination with insulin, is a safe, effective treatment option and more acceptable to women with GDM. Metformin has shown to cause less weight gain during pregnancy with minimal risk of maternal and neonatal hypoglycemia. Keywords: Gestational Diabetes Mellitus; Metformin; Insulin

scholarly journals Glycemic Control and Neonatal Outcomes in Women With Gestational Diabetes Mellitus Treated Using Glyburide, Metformin, or Insulin: A Pairwise and Network Meta-Analysis

2021 ◽  
Author(s):  
Dan-Qing Yu ◽  
Guan-Xin Xu ◽  
Xin-Yuan Teng ◽  
Jing-Wei Xu ◽  
Liang-Fang Tang ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Glycemic Control ◽  
Gestational Diabetes ◽  
Gestational Diabetes Mellitus ◽  
Meta Analysis ◽  
Postprandial Blood Glucose ◽  
Maternal Weight ◽  
Insulin Group ◽  
Standard Mean Difference ◽  
Metformin Group

Abstract Aims: We aimed to assess the comparative efficiency and safety of the use of glyburide, metformin, and insulin in gestational diabetes mellitus (GDM).Methods: We searched for randomized controlled trials that compared glyburide, metformin, and insulin in GDM. Data regarding glycemic control and neonatal safety were collected and analyzed in pairwise and network meta-analyses.Results: A total of 4,683 individuals from 24 trials were included. Compared with glyburide, metformin reduced 2-hour postprandial blood glucose (2HPG) to a greater extent (standard mean difference (SMD) 0.18; 95% credible interval (CI) 0–0.36). There were significantly lower prevalences of neonatal hypoglycemia (risk difference (RD) −0.07; 95%CI−0.11–−0.03), neonatal intensive care unit (NICU) admission (RD−0.03; 95%CI−0.06–−0), and preeclampsia (RD−0.03; 95%CI−0.06–−0) in the metformin group than in the insulin group. The metformin group had significantly lower birth weight (SMD−0.25; 95%CI−0.41–−0.10) and maternal weight gain (SMD−0.61; 95%CI−0.86–−0.35) compared with the insulin group. Network meta-analysis suggested that metformin had the highest probability of successfully controlling glycemia and preventing neonatal complications.Conclusions: The present meta-analysis suggests that metformin may be as effective as insulin for glycemic control and is the most promising drug for the prevention of neonatal and maternal complications.

scholarly journals Glycemic control and neonatal outcomes in women with gestational diabetes mellitus treated using glyburide, metformin, or insulin: a pairwise and network meta-analysis

2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Dan-Qing Yu ◽  
Guan-Xin Xu ◽  
Xin-Yuan Teng ◽  
Jing-Wei Xu ◽  
Liang-Fang Tang ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Glycemic Control ◽  
Gestational Diabetes ◽  
Gestational Diabetes Mellitus ◽  
Meta Analysis ◽  
Postprandial Blood Glucose ◽  
Maternal Weight ◽  
Insulin Group ◽  
Standard Mean Difference ◽  
Metformin Group

Abstract Aims We aimed to assess the comparative efficiency and safety of the use of glyburide, metformin, and insulin in gestational diabetes mellitus (GDM). Methods We searched for randomized controlled trials that compared glyburide, metformin, and insulin in GDM. Data regarding glycemic control and neonatal safety were collected and analyzed in pairwise and network meta-analyses. Results A total of 4533 individuals from 23 trials were included. Compared with glyburide, metformin reduced 2-h postprandial blood glucose (2HPG) to a greater extent (standard mean difference (SMD) 0.18; 95% credible interval (CI) 0.01, 0.34). There were significantly lower prevalence of neonatal hypoglycemia (risk difference (RD) − 0.07; 95%CI − 0.11, − 0.02) and preeclampsia (RD − 0.03; 95%CI − 0.06, 0) in the metformin group than in the insulin group. The metformin group had significantly lower birth weight (SMD − 0.17; 95%CI − 0.25, − 0.08) and maternal weight gain (SMD − 0.61; 95%CI − 0.86,− 0.35) compared with the insulin group. Network meta-analysis suggested that metformin had the highest probability of successfully controlling glycemia and preventing neonatal complications. Conclusions The present meta-analysis suggests that metformin may be as effective as insulin for glycemic control and is the most promising drug for the prevention of neonatal and maternal complications.

445: The relationship between gestational weight gain and gestational diabetes mellitus

2015 ◽  
Vol 212 (1) ◽  
pp. S229
Author(s):  
Amy O'Higgins ◽  
Lisa O'Higgins ◽  
Anne Fennessy ◽  
Thomas McCartan ◽  
Laura Mullaney ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Weight Gain ◽  
Gestational Diabetes ◽  
Gestational Diabetes Mellitus ◽  
Gestational Weight Gain ◽  
Gestational Weight ◽  
The Relationship

Dietary Intakes in the Nutritional Management Of Gestational Diabetes Mellitus

2014 ◽  
Vol 75 (2) ◽  
pp. 64-71 ◽  
Author(s):  
Anne-Sophie Morisset ◽  
Julie Anne Côté ◽  
Andréanne Michaud ◽  
Julie Robitaille ◽  
Marie-Christine Dubé ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Weight Gain ◽  
Gestational Diabetes ◽  
Gestational Diabetes Mellitus ◽  
Group Interaction ◽  
Nutritional Intervention ◽  
P Value ◽  
Institute Of Medicine ◽  
Dietary Intakes ◽  
Post Intervention

Purpose: Changes were examined in energy intakes and percentage of energy from macronutrients in response to nutritional intervention in women with gestational diabetes mellitus (GDM). Methods: The study included 17 women with GDM and 27 women with normal glucose tolerance (controls). Women with GDM were followed by a multidisciplinary team; they received dietary counselling by a registered dietitian, and were prescribed diets with 40% to 45% energy from carbohydrate (CHO), 20% to 25% from protein, and 30% to 35% from fat. Dietary intakes were assessed with food frequency questionnaires before the intervention (26.9 ± 3.8 weeks) and after the intervention (32.6 ± 0.6 weeks). Results: After the intervention, women with GDM reduced their total energy intake to reach lower values than did controls (P value for time-group interaction ≤0.05). A concomitant reduction in total CHO and glucose intakes in women with GDM led to significantly lower values compared with intakes in controls (P values for time-group interaction ≤0.001 for all). The post-intervention rate of weight gain in women with GDM was within the Institute of Medicine (IOM)-recommended values, while the post-intervention rate of weight gain in controls was above IOM-recommended values (0.30 ± 0.27 versus 0.61 ± 0.50 kg/week, P≤0.05). Conclusions: These results suggest that this multidisciplinary medical and nutritional intervention was effective in the achievement of prescribed macronutrient distribution and controlling gestational weight gain in Canadian women with GDM.

Sign in / Sign up

Export Citation Format

Share Document